{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:47:46Z","timestamp":1777366066118,"version":"3.51.4"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.pharmthera.2024.108611","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T16:14:54Z","timestamp":1708445694000},"page":"108611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations"],"prefix":"10.1016","volume":"256","author":[{"given":"Maryam Mashhadi Abolghasem","family":"Shirazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayebeh Azam","family":"Saedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra Samadi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahnaz","family":"Nemati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Shiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Negahdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser Hashemi","family":"Goradel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2024.108611_bb0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fonc.2019.01182","article-title":"Oncolytic adenovirus\u2014\u2014A Nova for gene-targeted oncolytic viral therapy in HCC","volume":"9","author":"Abudoureyimu","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169532","article-title":"Cell-surface Integrins and CAR are both essential for adenovirus type 5 transduction of canine cells of lymphocytic origin","volume":"12","author":"Agarwal","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ijbiomac.2022.03.057","article-title":"A review on targeting tumor microenvironment: The Main paradigm shift in the MAb-based immunotherapy of solid tumors","volume":"207","author":"Aghanejad","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/cgt.2010.36","article-title":"Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies","volume":"17","author":"Alcayaga-Miranda","year":"2010","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0025","doi-asserted-by":"crossref","first-page":"14177","DOI":"10.1038\/s41598-017-14717-x","article-title":"Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system","volume":"7","author":"Aoyama","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0030","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/molecules25071508","article-title":"Tumor targeted Nanocarriers for immunotherapy","volume":"25","author":"Baeza","year":"2020","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108611_bb0035","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.3390\/cancers13246320","article-title":"Multiple treatment cycles of neural stem cell delivered oncolytic adenovirus for the treatment of glioblastoma","volume":"13","author":"Batalla-Covello","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 Disrupts Pancreatic Cancer Stroma and Exerts Antitumor Effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J. ImmunoTherap. Cancer"},{"issue":"22","key":"10.1016\/j.pharmthera.2024.108611_bb0045","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/0008-5472.CAN-11-2009","article-title":"Epithelial junction opener JO-1 improves monoclonal antibody therapy of Cancer","volume":"71","author":"Beyer","year":"2011","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/hum.2006.17.55","article-title":"Novel three-pronged strategy to enhance Cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus Dl520","volume":"17","author":"Bieler","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/v15020358","article-title":"A renaissance for oncolytic adenoviruses?","volume":"15","author":"Blanchette","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both Hexon and Fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033920","article-title":"Modification of Ad5 Hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses","volume":"7","author":"Bruder","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108611_bb0070","first-page":"1909","article-title":"Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1","volume":"113","author":"Carlisle","year":"2009","journal-title":"Blood, J. American Soc. Hematol."},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0075","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/sj.mt.6300264","article-title":"Human matrix Metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus","volume":"15","author":"Cheng","year":"2007","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2009.142","article-title":"Effect of Decorin on overcoming the extracellular matrix barrier for oncolytic Virotherapy","volume":"17","author":"Choi","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0085","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2015.01.005","article-title":"PH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis","volume":"205","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0090","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.biomac.5b00538","article-title":"Oncolytic adenovirus coated with multidegradable bioreducible Core-cross-linked Polyethylenimine for Cancer gene therapy","volume":"16","author":"Choi","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.biomaterials.2015.07.001","article-title":"Using a magnetic field to redirect an oncolytic adenovirus complexed with Iron oxide augments gene therapy efficacy","volume":"65","author":"Choi","year":"2015","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2217\/imt.15.116","article-title":"Interview with Robert Coffin, inventor of T-VEC: The first oncolytic immunotherapy approved for the treatment of Cancer","volume":"8","author":"Coffin","year":"2016","journal-title":"Immunotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0105","first-page":"1484","article-title":"Irradiation enhances the therapeutic effect of the oncolytic adenovirus XVir-N-31 in brain tumor initiating cells","volume":"44","author":"Czolk","year":"2019","journal-title":"Int. J. Mol. Med."},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108611_bb0110","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular Oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"18","key":"10.1016\/j.pharmthera.2024.108611_bb0115","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1128\/JVI.75.18.8772-8780.2001","article-title":"Heparan sulfate Glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5","volume":"75","author":"Dechecchi","year":"2001","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1006\/viro.1999.0171","article-title":"Heparan sulfate Glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions","volume":"268","author":"Dechecchi","year":"2000","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/nano11010144","article-title":"Development of a new hyaluronic acid based redox-responsive Nanohydrogel for the encapsulation of oncolytic viruses for Cancer immunotherapy","volume":"11","author":"Deng","year":"2021","journal-title":"Nanomaterials"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108611_bb0130","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2009.156","article-title":"Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian Hamster model","volume":"17","author":"Dhar","year":"2009","journal-title":"Mol. Ther."},{"issue":"22","key":"10.1016\/j.pharmthera.2024.108611_bb0135","doi-asserted-by":"crossref","first-page":"12249","DOI":"10.1128\/JVI.01584-07","article-title":"Fiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivo","volume":"81","author":"Di Paolo","year":"2007","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02846-x","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: An approach of complementary advantages","volume":"23","author":"Dong","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0145","series-title":"Analysis of different combinatory regimes on the antitumor efficacy of oncolytic YB-1 based Virotherapy in glioblastoma","author":"Ehrenfeld","year":"2022"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/antib9040059","article-title":"CD46 and oncologic interactions: Friendly fire against Cancer","volume":"9","author":"Elvington","year":"2020","journal-title":"Antibodies"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0155","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2020.11.FOCUS20853","article-title":"Delta-24 adenoviral therapy for glioblastoma: Evolution from the bench to bedside and future considerations","volume":"50","author":"Ene","year":"2021","journal-title":"Neurosurg. Focus."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0160","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cancers12041034","article-title":"Effect of transgene location, transcriptional control elements and transgene features in armed oncolytic adenoviruses","volume":"12","author":"Farrera-Sal","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.addr.2009.12.003","article-title":"HPMA copolymers for masking and retargeting of therapeutic viruses","volume":"62","author":"Fisher","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0170","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in Cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0175","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0180","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered Intratumorally to patients with recurrent head and neck Cancer","volume":"6","author":"Ganly","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0185","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.omtm.2020.06.010","article-title":"Transient chimeric Ad5\/37 Fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells","volume":"18","author":"Gao","year":"2020","journal-title":"Mol. Therapy-Meth. Clin. Develop."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0190","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2007.06.010","article-title":"Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration","volume":"122","author":"Gao","year":"2007","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0195","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/hum.2018.107","article-title":"A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0200","first-page":"1","article-title":"Phase 1 study of intravenous Administration of the Chimeric Adenovirus Enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. Immunotherap.oCancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0205","article-title":"Phase I, Multicenter, Open-Label Study of Intravenous VCN-01 Oncolytic Adenovirus with or without Nab-Paclitaxel plus Gemcitabine in Patients with Advanced Solid Tumors","volume":"10","author":"Garcia-Carbonero","year":"2022","journal-title":"J. Immunotherap.oCancer"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0210","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung Cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.12.022","article-title":"Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice","volume":"294","author":"Garofalo","year":"2019","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0220","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/pharmaceutics13070949","article-title":"Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108611_bb0225","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation-turning cold Tumours into hot","volume":"13","author":"Garofalo","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0230","article-title":"Clinical advances in oncolytic Virotherapy for pediatric brain tumors","volume":"108193","author":"Ghajar-Rahimi","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0235","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41594-022-00811-w","article-title":"Conformational buffering underlies functional selection in intrinsically disordered protein regions","volume":"29","author":"Gonzalez-Foutel","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"57","key":"10.1016\/j.pharmthera.2024.108611_bb0240","doi-asserted-by":"crossref","first-page":"31045","DOI":"10.18632\/oncotarget.25774","article-title":"Spatial and temporal proteome dynamics of glioma cells during oncolytic Adenovirus Delta-24-RGD infection","volume":"9","author":"Gonz\u00e1lez-Morales","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0245","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.actbio.2021.07.047","article-title":"Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-Cancer therapeutic efficacy","volume":"134","author":"Gonzalez-Pastor","year":"2021","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108611_bb0250","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1002\/jcp.27850","article-title":"Oncolytic adenovirus: A tool for Cancer therapy in combination with other therapeutic approaches","volume":"234","author":"Goradel","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0255","article-title":"Strategies for enhancing Intratumoral spread of oncolytic adenoviruses","volume":"107586","author":"Goradel","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic Virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0265","article-title":"Nanovaccines for Cancer immunotherapy: Focusing on complex formation between adjuvant and antigen","volume":"117","author":"Goradel","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0270","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2217\/nnm.12.50","article-title":"Tropism ablation and Stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves Virotherapy of Cancer","volume":"7","author":"Green","year":"2012","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0275","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/hum.2007.034","article-title":"Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in Orthotopic lung and breast tumors","volume":"18","author":"Hakkarainen","year":"2007","journal-title":"Hum. Gene Ther."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0280","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/jcp.26029","article-title":"Nanoparticles as new tools for inhibition of Cancer angiogenesis","volume":"233","author":"Hashemi","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0285","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41598-017-02279-x","article-title":"Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate Cancer","volume":"7","author":"Heumann","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101671","article-title":"Full encapsulation of oncolytic virus using hybrid Erythroctye-liposome membranes for augmented anti-refractory tumor effectiveness","volume":"47","author":"Huang","year":"2022","journal-title":"Nano Today"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108611_bb0295","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1002\/1873-3468.13717","article-title":"Cell transformation by the adenovirus oncogenes E1 and E4","volume":"594","author":"Ip","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0300","article-title":"Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus","volume":"40","author":"Iscaro","year":"2022","journal-title":"Nanomedicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0305","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.3390\/app10082872","article-title":"Optimising hydrogel release profiles for Viro-immunotherapy using oncolytic adenovirus expressing IL-12 and GM-CSF with immature dendritic cells","volume":"10","author":"Jenner","year":"2020","journal-title":"Appl. Sci."},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108611_bb0310","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous Cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0315","doi-asserted-by":"crossref","first-page":"10533","DOI":"10.1021\/acsnano.6b06530","article-title":"Mild hyperthermia induced by gold Nanorod-mediated Plasmonic Photothermal therapy enhances transduction and replication of oncolytic adenoviral gene delivery","volume":"10","author":"Jung","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","article-title":"A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response","volume":"147","author":"Jung","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0325","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing Relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic Cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0330","article-title":"Applications of nanotechnology in virus detection, tracking, and infection mechanisms","volume":"13","author":"Kang","year":"2021","journal-title":"Wiley Interdisciplin. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0335","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2017.08.035","article-title":"Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus","volume":"145","author":"Kasala","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0340","series-title":"A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults","author":"Keefer","year":"2012"},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0345","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.biomaterials.2009.11.043","article-title":"The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in Cancer gene therapy","volume":"31","author":"Kim","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/OV.S196403","article-title":"Preclinical and clinical development of oncolytic adenovirus for the treatment of malignant glioma","author":"Kiyokawa","year":"2019","journal-title":"Oncolyt. Virotherap."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0355","first-page":"158","article-title":"Pan-Cancer molecular analysis of the RB tumor suppressor pathway","volume":"3","author":"Knudsen","year":"2020","journal-title":"Communicat. Biol."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0360","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/s41467-022-32087-5","article-title":"Targeting the retinoblastoma\/E2F repressive complex by CDK4\/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus","volume":"13","author":"Koch","year":"2022","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.pharmthera.2024.108611_bb0365","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1128\/JVI.77.24.13062-13072.2003","article-title":"Reduction of natural adenovirus tropism to mouse Liverby Fiber-shaft exchange in combination with both CAR-And\u03b1v integrin-BindingAblation","volume":"77","author":"Koizumi","year":"2003","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060032","article-title":"Mutation of the Fiber shaft Heparan Sulphate binding site of a 5\/3 chimeric adenovirus reduces liver tropism","volume":"8","author":"Koski","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0375","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.mt.6300094","article-title":"Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop","volume":"15","author":"Kritz","year":"2007","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0380","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jconrel.2013.03.030","article-title":"Therapeutic targeting of chitosan\u2013PEG\u2013folate-complexed oncolytic adenovirus for active and systemic Cancer gene therapy","volume":"169","author":"Kwon","year":"2013","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.pharmthera.2024.108611_bb0385","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1039\/C9BM00992B","article-title":"Physically crosslinked injectable hydrogels for long-term delivery of oncolytic adenoviruses for Cancer treatment","volume":"7","author":"Le","year":"2019","journal-title":"Biomater. Sci."},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2024.108611_bb0390","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/hum.2021.247","article-title":"M11: A tropism-modified oncolytic adenovirus arming with a tumor-homing peptide for advanced ovarian Cancer therapies","volume":"33","author":"Li","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0395","series-title":"CORE1: Phase 2, Single-Arm Study of CG0070 Combined with Pembrolizumab in Patients with Nonmuscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)","author":"Li","year":"2022"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0400","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"issue":"13_Supplement","key":"10.1016\/j.pharmthera.2024.108611_bb0405","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/1538-7445.AM2021-1148","article-title":"SynOV1. 1: A synthetic gene circuit controlled oncolytic adenovirus demonstrating high tumor specificity, potent antitumor efficacy and high synergy with an anti-PD-L1 monoclonal antibody in preclinical hepatocellular carcinoma models","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0410","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane Nanovesicles for oncolytic adenovirus delivery: A versatile platform for Cancer Virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"issue":"22","key":"10.1016\/j.pharmthera.2024.108611_bb0415","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1039\/D1BM00928A","article-title":"Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and Virotherapy","volume":"9","author":"Lv","year":"2021","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0420","first-page":"1","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus Enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunotherap.oCancer"},{"issue":"16","key":"10.1016\/j.pharmthera.2024.108611_bb0425","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.3390\/ijms23168884","article-title":"Complexing the oncolytic adenoviruses ad\u2206\u2206 and Ad-3\u2206-A20T with cationic nanoparticles enhances viral infection and spread in prostate and pancreatic Cancer models","volume":"23","author":"Man","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.pharmthera.2024.108611_bb0430","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.3390\/ijms221910522","article-title":"Concepts in oncolytic adenovirus therapy","volume":"22","author":"Mantwill","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in Cancer immunotherapy","volume":"8","author":"M\u00e4rkl","year":"2022","journal-title":"Trend. Cancer."},{"issue":"13_Supplement","key":"10.1016\/j.pharmthera.2024.108611_bb0440","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1158\/1538-7445.AM2018-4053","article-title":"Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapsis in breast Cancer","volume":"78","author":"Martinez","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0445","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/mt.2014.204","article-title":"Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy","volume":"23","author":"Martinez-Quintanilla","year":"2015","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0450","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (ad) Type-5, Type-6, Type-26 and Type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jconrel.2021.02.035","article-title":"Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11","volume":"332","author":"Mato-Berciano","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0460","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3389\/fonc.2019.01227","article-title":"Nanoparticle delivery and tumor vascular normalization: The chicken or the egg?","volume":"9","author":"Mattheolabakis","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0465","doi-asserted-by":"crossref","first-page":"20220517","DOI":"10.1515\/ntrev-2022-0517","article-title":"Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in Nanocarriers\u2019 development","volume":"12","author":"Mohammed","year":"2023","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biomaterials.2014.11.021","article-title":"Dual tumor targeting with PH-sensitive and bioreducible polymer-complexed oncolytic adenovirus","volume":"41","author":"Moon","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0475","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2147\/DDDT.S219489","article-title":"Smart targeting to improve Cancer therapeutics","author":"Morales-Cruz","year":"2019","journal-title":"Drug Design, Developm. Therapy"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0480","doi-asserted-by":"crossref","first-page":"S853","DOI":"10.1016\/j.annonc.2021.08.1395","article-title":"1011P FORTITUDE phase I study of NG-350A, a novel tumour-selective adenoviral vector expressing an anti-CD40 agonist antibody: Monotherapy dose escalation results","volume":"32","author":"Naing","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0485","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1128\/JVI.77.4.2512-2521.2003","article-title":"Reduction of natural adenovirus tropism to the liver by both ablation of Fiber-Coxsackievirus and adenovirus receptor interaction and use of replaceable Short Fiber","volume":"77","author":"Nakamura","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0490","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/IJN.S386560","article-title":"Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated Thiolated chitosan as a Green Nanoformulation for the treatment of prostate Cancer: A Viro-immunotherapeutic approach","author":"Naseer","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0495","first-page":"1","article-title":"Oncolytic DNX-2401 Virotherapy plus Pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"issue":"March","key":"10.1016\/j.pharmthera.2024.108611_bb0500","first-page":"663","article-title":"Infection of non-Cancer cells\u00a0: A barrier or support for oncolytic Virotherapy\u00a0?","volume":"24","author":"Naumenko","year":"2022","journal-title":"Mol. Therap.: Oncolyt."},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0505","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.18632\/oncotarget.13972","article-title":"Oncolytic adenovirus Coexpressing Interleukin-12 and Decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model","volume":"8","author":"Oh","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for Cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0515","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol. Therapy-Oncolyt."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0520","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1038\/s41598-022-26030-3","article-title":"Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus","volume":"12","author":"Ono","year":"2022","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108611_bb0525","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than P53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"O\u2019Shea","year":"2004","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0530","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0535","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1128\/JVI.02372-13","article-title":"Adenovirus E1B 19-Kilodalton protein modulates innate immunity through apoptotic mimicry","volume":"88","author":"Radke","year":"2014","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0540","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jgm.1565","article-title":"Switching the Fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human Cancer patients","volume":"13","author":"Raki","year":"2011","journal-title":"J. Gene Med."},{"issue":"7","key":"10.1016\/j.pharmthera.2024.108611_bb0545","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2013.509","article-title":"Presence of the Coxsackievirus and adenovirus receptor (CAR) in human neoplasms: A Multitumour Array analysis","volume":"109","author":"Reeh","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.pharmthera.2024.108611_bb0550","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1158\/1078-0432.CCR-14-2213","article-title":"Safety and efficacy of VCN-01, an oncolytic adenovirus combining Fiber HSG-binding domain replacement with RGD and hyaluronidase expression","volume":"21","author":"Rodr\u00edguez-Garc\u00eda","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0555","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2016.07.004","article-title":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","volume":"237","author":"Rojas","year":"2016","journal-title":"J. Control. Release"},{"issue":"26","key":"10.1016\/j.pharmthera.2024.108611_bb0560","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.7150\/thno.37568","article-title":"Engineering nanoparticles to reprogram the tumor immune microenvironment for improved Cancer immunotherapy","volume":"9","author":"Saeed","year":"2019","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.pharmthera.2024.108611_bb0565","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3390\/bioengineering9110620","article-title":"Development of adenovirus containing liposomes produced by extrusion vs. homogenization: A comparison for scale-up purposes","volume":"9","author":"Shah","year":"2022","journal-title":"Bioengineering"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0570","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2016.12.020","article-title":"Adenovirus transduction: More complicated than receptor expression","volume":"502","author":"Sharma","year":"2017","journal-title":"Virology"},{"issue":"14","key":"10.1016\/j.pharmthera.2024.108611_bb0575","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1158\/0008-5472.CAN-08-0488","article-title":"Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus","volume":"68","author":"Shashkova","year":"2008","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.pharmthera.2024.108611_bb0580","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1535-7163.MCT-10-0332","article-title":"Substitution of adenovirus serotype 3 Hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy","volume":"9","author":"Short","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0585","series-title":"Patients with metastatic\/advanced epithelial Tumours (STAR)","article-title":"762 first-in-human phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module","author":"Simon","year":"2022"},{"issue":"3","key":"10.1016\/j.pharmthera.2024.108611_bb0590","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00430-019-00645-2","article-title":"Human adenovirus binding to host cell receptors: A structural view","volume":"209","author":"Stasiak","year":"2020","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0595","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.virusres.2018.08.012","article-title":"Tropism and transduction of oncolytic adenovirus 5 vectors in Cancer therapy: Focus on Fiber Chimerism and mosaicism, Hexon and PIX","volume":"257","author":"Stepanenko","year":"2018","journal-title":"Virus Res."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0600","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omto.2021.12.013","article-title":"Superior infectivity of the Fiber chimeric oncolytic adenoviruses Ad5\/35 and Ad5\/3 over Ad5-Delta-24-RGD in primary glioma cultures","volume":"24","author":"Stepanenko","year":"2022","journal-title":"Mol. Therapy-Oncolyt."},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0605","article-title":"Triple-Serotype Chimeric Oncolytic Adenovirus Exerts Multiple Synergistic Mechanisms against Solid Tumors","volume":"10","author":"Su","year":"2022","journal-title":"J. Immunotherap.oCancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0610","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0615","first-page":"45","article-title":"Oncolytic adenovirus-mediated therapy for prostate Cancer","author":"Sweeney","year":"2016","journal-title":"Oncolyt. Virotherap."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588682","article-title":"The role of GITR\/GITRL interaction in autoimmune diseases","volume":"11","author":"Tian","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0625","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/mp100123t","article-title":"Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force","volume":"7","author":"Tresilwised","year":"2010","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0630","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.biomaterials.2011.09.028","article-title":"Effects of Nanoparticle Coatings on the Activity of Oncolytic Adenovirus\u2013Magnetic Nanoparticle Complexes","volume":"33","author":"Tresilwised","year":"2012","journal-title":"Biomaterials"},{"issue":"17","key":"10.1016\/j.pharmthera.2024.108611_bb0635","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","article-title":"Ad5NULL-A20: A tropism-modified, \u0391v\u03b26 integrin-selective oncolytic adenovirus for epithelial ovarian Cancer therapies","volume":"24","author":"Uusi-Kerttula","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0640","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0645","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.pharmthera.2024.108611_bb0650","doi-asserted-by":"crossref","first-page":"10841","DOI":"10.1128\/JVI.01425-15","article-title":"Intracellular signaling and Desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1","volume":"89","author":"Wang","year":"2015","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0655","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond Oncolysis of tumor cells for Cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunotherap.oCancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2024.108611_bb0660","doi-asserted-by":"crossref","first-page":"2096362","DOI":"10.1080\/2162402X.2022.2096362","article-title":"Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian Cancer","volume":"11","author":"Wang","year":"2022","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.pharmthera.2024.108611_bb0665","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.3390\/v13122502","article-title":"Adenovirus biology, recombinant adenovirus, and adenovirus usage in gene therapy","volume":"13","author":"Watanabe","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.pharmthera.2024.108611_bb0670","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/hum.2017.212","article-title":"Fighting Cancer with viruses: Oncolytic virus therapy in China","volume":"29","author":"Wei","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"16_Supplement","key":"10.1016\/j.pharmthera.2024.108611_bb0675","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1538-7445.AM2020-915","article-title":"Abscopal effect using Intratumoral oncolytic Virotherapy (LOAd703) is enhanced by anti-PD-1 or anti-PD-L1","volume":"80","author":"Wenthe","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0680","article-title":"Oncolytic adenovirus-loaded magnetic-driven Janus tumor cell robots for active and targeted Virotherapy of homologous carcinoma","volume":"30","author":"Xie","year":"2023","journal-title":"Mater. Today Chem."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0685","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2014.07.053","article-title":"A targeting ligand enhances infectivity and cytotoxicity of an oncolytic adenovirus in human pancreatic Cancer tissues","volume":"192","author":"Yamamoto","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0690","series-title":"Combined Therapy with Cytokine-Induced Killer Cells and Oncolytic Adenovirus Expressing IL-12 Induce Enhanced Antitumor Activity in Liver Tumor Model","author":"Yang","year":"2012"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0695","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2016.02.046","article-title":"Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in Orthotopic lung tumor model","volume":"231","author":"Yoon","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.pharmthera.2024.108611_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2019.104619","article-title":"Control Sonochemical parameter to prepare pure Zn0. 35Fe2. 65O4 nanostructures and study their photocatalytic activity","volume":"58","author":"Yousefi","year":"2019","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.pharmthera.2024.108611_bb0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.116405","article-title":"Synthesis, characterization and application of co\/Co3O4 nanocomposites as an effective Photocatalyst for discoloration of organic dye contaminants in wastewater and antibacterial properties","volume":"337","author":"Yousefi","year":"2021","journal-title":"J. Mol. Liq."},{"issue":"4","key":"10.1016\/j.pharmthera.2024.108611_bb0710","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models","volume":"27","author":"Yumul","year":"2016","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.pharmthera.2024.108611_bb0715","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41417-021-00389-3","article-title":"Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 Orthotopic mouse model","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.pharmthera.2024.108611_bb0720","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/mt.2011.29","article-title":"Optimizing DC vaccination by combination with oncolytic adenovirus Coexpressing IL-12 and GM-CSF","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725824000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:39:55Z","timestamp":1759012795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725824000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":144,"alternative-id":["S0163725824000317"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108611","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108611"}}